Lead optimization in the nondrug-like space

Drug Discovery Today

Volumn 16, Issue 3-4, 2011, Pages 158-163

  Zhao, Hongyu ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; ALISKIREN; AMIODARONE; ANACETRAPIB; ASTEMIZOLE; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; LAPATINIB; MIPROXIFENE PHOSPHATE; PENFLURIDOL; PHOSPHOPROTEIN PHOSPHATASE; PIMOZIDE; PLACEBO; PROTEIN; PROTEIN BCL 2; TORCETRAPIB; XIMELAGATRAN;

CLINICAL PROTOCOL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG MARKETING; DRUG POTENCY; DRUG RESEARCH; DRUG SOLUBILITY; DRUG TARGETING; HYDROPHOBICITY; LIPOPHILICITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REACTION OPTIMIZATION; REVIEW; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; HUMANS; LIGANDS; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TECHNOLOGY, PHARMACEUTICAL;

EID: 79851514658     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.12.002     Document Type: Review

References (46)

1. C.A. Lipinski Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 23 1997 3 25 (Pubitemid 27046991)
2. D.F. Veber Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 45 2002 2615 2623 (Pubitemid 34595232)
3. M.C. Wenlock A comparison of physiochemical property profiles of development and marketed oral drugs J. Med. Chem. 46 2003 1250 1256 (Pubitemid 36428230)
4. F. Lovering Escape from flatland: increasing saturation as an approach to improving clinical success J. Med. Chem. 52 2009 6752 6756
5. C. Abad-Zapatero A Sorcerer's apprentice and The Rule of Five: from rule-of-thumb to commandment and beyond Drug Discov. Today 12 2007 995 997 (Pubitemid 350186134)
6. P.D. Leeson Drug-like properties: guiding principles for design - or chemical prejudice? Drug Discov. Today: Technol. 1 2004 189 195 (Pubitemid 40197566)
7. N. Fotouhi Lead generation: reality check on commonly held views Expert Opin. Drug Discov. 3 2008 733 744
8. J.P. Overington How many drug targets are there? Nat. Rev. Drug Discov. 5 2006 993 996 (Pubitemid 44835126)
9. M. Weatherall An end to the search for new drugs? Nature 296 1982 387 390 (Pubitemid 12108521)
10. G. Vistoli Assessing drug-likeness - what are we missing? Drug Discov. Today 13 2008 285 294
11. S.W. Muchmore Cheminformatic tools for medicinal chemists J. Med. Chem. 53 2010 4830 4841
12. M.J. Waring Lipophilicity in drug discovery Expert Opin. Drug Discov. 5 2010 235 248
13. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 2004 711 715 (Pubitemid 39173511)
14. G.M. Grass, and P.J. Sinko Effect of diverse datasets on the predictive capability of ADME models in drug discovery Drug Discov. Today 6 Suppl. 1 2001 54 61
15. J.D. Hughes Physiochemical drug properties associated with in vivo toxicological outcomes Bioorg. Med. Chem. Lett. 18 2008 4872 4875
16. M. Vieth, and J.J. Sutherland Dependence of molecular properties on proteomic family for marketed oral drugs J. Med. Chem. 49 2006 3451 3453 (Pubitemid 43902452)
17. T.I. Oprea Is there a difference between leads and drugs? J. Chem. Inf. Comput. Sci. 41 2001 1308 1315
18. M.M. Hann Molecular complexity and its impact on the probability of finding leads for drug discovery J. Chem. Inf. Comput. Sci. 41 2001 856 864
19. F. Lombardo Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data J. Med. Chem. 45 2002 2867 2876 (Pubitemid 34627657)
20. C.A. Lipinski Lead- and drug-like compounds: the-rule-of-five revolution Drug Discov. Today: Technol. 1 2004 337 341 (Pubitemid 40186335)
21. J.C. Fuller Predicting druggable binding sites at the protein-protein interface Drug Discov. Today 14 2009 155 161
22. M.R. Arkin, and J.A. Wells Small-molecule inhibitors of protein-protein interactions: progressing towards the dream Nat. Rev. Drug Discov. 3 2004 301 317 (Pubitemid 38499758)
23. C. Tse ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Res. 68 2008 3421 3428
24. T. Berg Small-molecule inhibitors of protein-protein interactions Curr. Opin. Drug Discov. Dev. 11 2008 666 674
25. J.A. Sikorski Oral cholesteryl ester transfer protein (CETP) inhibitors: a potential new approach for treating coronary artery disease J. Med. Chem. 49 2006 1 22 (Pubitemid 43077315)
26. P.J. Barter Effects of torcetrapib in patients at high risk for coronary events N. Engl. J. Med. 357 2007 2109 2122 (Pubitemid 350146106)
27. T.O. Johnson Protein tyrosine phosphatase 1B inhibitors for diabetes Nat. Rev. Drug Discov. 1 2002 696 709 (Pubitemid 37368828)
28. G. Liu Fragment screening and assembly: a highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor J. Med. Chem. 46 2003 4232 4235 (Pubitemid 37153003)
29. A.L. Hopkins Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 16 2006 127 136 (Pubitemid 43221881)
30. R. Morphy, and Z. Rankovic Fragments, network biology and designing multiple ligands Drug Discov. Today 12 2007 156 160 (Pubitemid 46176667)
31. B.L. Roth Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia Nat. Rev. Drug Discov. 3 2004 353 359 (Pubitemid 38499762)
32. R. Morphy, and Z. Rankovic The physicochemical challenges of designing multiple ligands J. Med. Chem. 49 2006 4961 4970 (Pubitemid 44201054)
33. K.E. Lackey Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor Curr. Top. Med. Chem. 6 2006 435 460
34. D.M. Roden Antiarrhythmic drugs: past, present, and future J. Cardiovasc. Electrophysiol. 14 2003 1389 1396 (Pubitemid 38037485)
35. J. Menard, and M. Azizi The difficult conception, birth, and delivery of a rennin inhibitor: controversies around aliskiren J. Hypertens. 25 2007 1775 1782 (Pubitemid 47364583)
36. J.L. LaMattina Drug Truths: Dispelling the Myths About Pharma R&D 2009 John Wiley & Sons Inc.
37. V.J. Stella, and K.W. Nti-Addae Prodrug strategies to overcome poor water solubility Adv. Drug Deliv. Rev. 59 2007 677 694 (Pubitemid 47285410)
38. Y. Nomura Phase I study of TAT-59 (a new antiestrogen) in breast cancer Gan To Kagaku Ryoho 25 1998 553 561
39. M.Q. Zhang, and B. Wilkinson Drug discovery beyond the "rule-of-five" Curr. Opin. Biotechnol. 18 2007 478 488
40. H.K.M. Molinder The development of cimetidine: 1964-1976. A human story J. Clin. Gastroenterol. 19 1994 248 254 (Pubitemid 24302045)
41. D.T. Wong The discovery of fluoxetine hydrochloride (prozac) Nat. Rev. Drug Discov. 4 2005 764 774
42. R.R. Ruffolo, and G.Z. Feuerstein Carvedilol case history: the discovery and development of the first β-blocker for the treatment of congestive heart failure Expert Opin. Drug Discov. 1 2006 85 89
43. P. Cuatrecasas Drug discovery in jeopardy J. Clin. Invest. 116 2006 2837 2842 (Pubitemid 44684465)
44. M. Williams Perseverance furthers? The role of the drug hunter in the postgenomic era Curr. Opin. Investig. Drugs 9 2008 21 27
45. J. Black A personal perspective on Dr. Paul Janssen J. Med. Chem. 48 2005 1687 1688
46. S.M. Paul How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214